The global pharmaceutical industry experienced an 18% drop in company filings mentions of regenerative medicine in Q2 2024 compared with the previous quarter, with the highest share accounted for by Sarepta Therapeutics with 16% year-on-year decrease, according to GlobalData’s analysis of over 351 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q2 2024 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Pharma: Filings Trends & Signals Q2 2024

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Notably, regenerative medicine was one of the most frequently referenced themes in Q2 2024, ranking highest in terms of mentions, ahead of 3d printing and edtech, according to GlobalData.

Of the top leading companies in the pharmaceutical industry, Sarepta Therapeutics had the greatest increase in references for regenerative medicine in Q2 2024, compared with the previous quarter. GlobalData identified 31 regenerative medicine-related sentences in the company's filings - 2% of all sentences - and a decrease of 16% in Q2 2024 compared with Q2 2023. Bristol-Myers Squibb’s mentions of regenerative medicine dropped by 70% to 17 and Lonza Group’s by 300% to 16 and Gilead Sciences’s by 70% to 15 and BioMarin Pharmaceutical’s by 19% to 13.

GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for regenerative medicine in Q2 2024 was 98.

For further understanding of GlobalData's Pharma: Filings Trends & Signals Q2 2024, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.